Find Funding Opportunities

This Funding Opportunity Announcement (FOA) invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this FOA are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

The NIH Countermeasures Against Chemical Threats (CounterACT) program intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the discovery and early-stage development of safe and effective new and repurposed drug candidates to mitigate the health effects resulting from exposure to highly toxic chemical threats. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The purpose of this Notice is to alert potential applicants to the early expiration of PAR-20-316 "NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)". This FOA will expire on October 1, 2021.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.

Notice Change Key Dates PAR-19-040 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)" Notice Number: NOT-NS-20-088 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-040 - Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-040 "Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice Change Key Dates PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Notice Number: NOT-NS-20-086 Key Dates Release Date: July 10, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; September 9, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date September 10, 2020 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; October 8, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date October 9, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email: jettd@ninds.nih.gov

Notice Change Key Dates PAR-19-039 Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)" Notice Number: NOT-NS-20-087 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-039 - Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-039 "Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)" Notice Number: NOT-NS-20-085 Key Dates Release Date: July 8, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) NOT-NS-18-072 - Rescinded - Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform applicants a change the Application Budgets PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". notice updates, supercedes replaces previous notice, NOT-NS-18-072 "Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Specifically, application budgets be reduced 2 million direct costs per yearto 1.75 million direct costs per year. notice be effective the October 8, 2020 receipt date. Change shown below bold italics. Currently Reads: Section II. Award Information Award Budget Application budgets not exceed 2.0 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Section II. Award Information Award Budget Application budgets not exceed 1.75 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email:jettd@ninds.nih.gov

Notice Change Key Dates PAR-18-721 Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)" Notice Number: NOT-NS-20-064 Key Dates Release Date: 6, 2020 Related Announcements PAR-18-721 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-721 "Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)." Specifically, last receipt date been changed June 30, 2020 the new expiration date this FOA be July 1, 2020. Changes the FOA shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; 26, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date 27, 2020 Modified Read: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; June 30, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date July 1, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Shardell Spriggs, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional). Notice Number: NOT-NS-18-072 Key Dates Release Date: June 14, 2018 Related Announcements NOT-NS-20-085 PAR-18-657 Issued National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to amend award budget PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)." Section II. Award Information Currently Reads: Award Budget Application budgets not exceed 2.5 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Award Budget Application budgets not exceed $2.0 million in direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain same. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-6035 Email: jettd@ninds.nih.gov